Increased neurokinin-1 receptor availability in the amygdala in social anxiety disorder: A positron emission tomography study with [11C]GR205171

Translational Psychiatry

Volumn 5, Issue , 2015, Pages

  Frick, A ^a   Ahs, F ^a,b   Linnman, C ^c   Jonasson, M ^a   Appel, L ^a   Lubberink, M ^a   Langstrom B ^a   Fredrikson, M ^a,b   Furmark, T ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROKININ 1 RECEPTOR; TRACER; NEUROKININ 1 RECEPTOR ANTAGONIST; PIPERIDINE DERIVATIVE; TETRAZOLE DERIVATIVE; VOFOPITANT;

ADULT; ALCOHOL CONSUMPTION; AMYGDALOID NUCLEUS; ANTERIOR CINGULATE; ARTICLE; BODY WEIGHT; BRAIN ANALYSIS; CEREBELLUM; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; FEMALE; GENOTYPE; HIPPOCAMPUS; HUMAN; INSULA; MALE; NEUROTRANSMISSION; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; SOCIAL PHOBIA; AMYGDALA; CASE CONTROL STUDY; CHEMISTRY; METABOLISM; NEUROIMAGING; PATHOPHYSIOLOGY; PHOBIA; PHYSIOLOGY;

ADULT; AMYGDALA; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; NEUROIMAGING; NEUROKININ-1 RECEPTOR ANTAGONISTS; PHOBIC DISORDERS; PIPERIDINES; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, NEUROKININ-1; TETRAZOLES;

EID: 84936875113     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2015.92     Document Type: Article

References (66)

1. Shin LM, Liberzon I. The neurocircuitry of fear, stress, and anxiety disorders. Neuropsychopharmacology 2010; 35: 169-191.
2. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry 2005; 62: 593-602.
3. Ohkubo H, Nakanishi S. Molecular characterization of the three tachykinin receptors. Ann N Y Acad Sci 1991; 632: 53-62.
4. Von Euler US, Gaddum JH. An unidentified depressor substance in certain tissue extracts. J Physiol 1931; 72: 74-87.
5. Ribeiro-da-Silva A, Hökfelt T. Neuroanatomical localisation of substance P in the CNS and sensory neurons. Neuropeptides 2000; 34: 256-271.
6. Ebner K, Singewald N. The role of substance P in stress and anxiety responses. Amino Acids 2006; 31: 251-272.
7. Mathew SJ, Price RB, Charney DS. Recent advances in the neurobiology of anxiety disorders: implications for novel therapeutics. Am J Med Genet 2008; 148C:89-98.
8. Ebner K, Muigg P, Singewald G, Singewald N. Substance P in stress and anxiety. Ann N Y Acad Sci 2008; 1144: 61-73.
9. Ebner K, Rupniak NM, Saria A, Singewald N. Substance P in the medial amygdala: emotional stress-sensitive release and modulation of anxiety-related behavior in rats. Proc Natl Acad Sci USA 2004; 101: 4280-4285.
10. Geracioti TD Jr, Carpenter LL, Owens MJ, Baker DG, Ekhator NN, Horn PS et al. Elevated cerebrospinal fluid substance P concentrations in posttraumatic stress disorder and major depression. Am J Psychiatry 2006; 163: 637-643.
11. Michelgård Å, Appel L, Pissiota A, Frans O¨, Långström B, Bergström et al. Symptom provocation in specific phobia affects the substance P neurokinin-1 receptor system. Biol Psychiatry 2007; 61: 1002-1006.
12. Bassi GS, de Carvalho MC, Brandão ML. Effects of substance P and Sar-Met-SP, a NK1 agonist, in distinct amygdaloid nuclei on anxiety-like behavior in rats. Neurosci Lett 2014; 569: 121-125.
13. Pringle A, McTavish SF, Williams C, Smith R, Cowen PJ, Harmer CJ. Short-term NK1 receptor antagonism and emotional processing in healthy volunteers. Psychopharmacology 2011; 215: 239-246.
14. Furmark T, Appel L, Michelgård Å, Wahlstedt K, Åhs F, Zancan S et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol Psychiatry 2005; 58: 132-142.
15. Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998; 281: 1640-1645.
16. Keller M, Montgomery S, Ball W, Morrison M, Snavely D, Liu G et al. Lack of efficacy of the substance P (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry 2006; 59: 216-223.
17. nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder. Eur Neuropsychopharmacol 2010; 20: 80-87.
18. Michelson D, Hargreaves R, Alexander R, Ceesay P, Hietala J, Lines C et al. Lack of efficacy of L-759274, a novel neurokinin 1 (substance P) receptor antagonist, for the treatment of generalized anxiety disorder. Int J Neuropsychopharmacol 2013; 16: 1-11.
19. Mathew SJ, Vythilingam M, Murrough JW, Zarate CA Jr., Feder A, Luckenbaugh DA et al. A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial. Eur Neuropsychopharmacol 2011; 21: 221-229.
20. Kramer MS, Winokur A, Kelsey J, Preskorn SH, Rothschild AJ, Snavely D et al. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology 2004; 29: 385-392.
21. Fujimura Y, Yasuno F, Farris A, Liow J-S, Geraci M, Drevets W et al. Decreased neurokinin-1 (substance P) receptor binding in patients with panic disorder: positron emission tomographic study with [18F]SPA-RQ. Biol Psychiatry 2009; 66: 94-97.
22. Tillfors M, Furmark T, Marteinsdottir I, Fischer H, Pissiota A, Långström B et al. Cerebral blood flow in subjects with social phobia during stressful speaking tasks: a PET study. Am J Psychiatry 2001; 158: 1220-1226.
23. Brühl AB, Delsignore A, Komossa K, Weidt S. Neuroimaging in social anxiety disorder - A meta-analytic review resulting in a new neurofunctional model. Neurosci Biobehav Rev 2014; 47: 260-280.
24. Bergström M, Fasth K-J, Kilpatrick G, Ward P, Cable KM, Wipperman MD et al. Brain uptake and receptor binding of two [11C]labelled selective high affinity NK1-antagonists, GR203040 and GR205171 - PET studies in rhesus monkey. Neuropharmacology 2000; 39: 664-670.
25. First MB, Gibbon M, Spitzer RL, Williams JBW. SCID-I: Interview Protocol (Swedish). Pilgrim Press: Stockholm, Sweden, 1998.
26. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59: 22-33.
27. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition Text Revision American Psychiatric Publishing: Washington, DC, USA, 2000.
28. Fresco DM, Coles ME, Heimberg RG, Liebowitz MR, Hami S, Stein MB et al. The Liebowitz social anxiety scale: a comparison of the psychometric properties of self-report and clinician-administered formats. Psychol Med 2001; 31: 1025-1035.
29. Griffante C, Carletti R, Andreetta F, Corsi M. [3H]GR205171 displays similar NK1 receptor binding profile in gerbil and human brain. Br J Pharmacol 2006; 148: 39-45.
30. Gardner CJ, Armour DR, Beattie DT, Gale JD, Hawcock AB, Kilpatrick GJ et al. GR205171: a novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity. Regul Pept 1996; 65: 45-53.
31. Bergström M, Kumlien E, Lilja A, Tyrefors N, Westerberg G, Långström B. Temporal lobe epilepsy visualized with PET with 11C-L-deuterium-deprenyl - analysis of kinetic data. Acta Neurol Scand 1998; 98: 224-231.
32. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983; 3: 1-7.
33. Hietala J, Nyman MJ, Eskola O, Laakso A, Grönroos T, Oikonen V et al. Visualization and quantification of neurokinin-1 (NK1) receptors in the human brain. Mol Imaging Biol 2005; 7: 262-272.
34. Svarer C, Madsen K, Hasselbalch SG, Pinborg LH, Haugbøl S, Frøkjaer VG et al. MR-based automatic delineation of volumes of interest in human brain PET images using probability maps. Neuroimage 2005; 24: 969-979.
35. Maldjian JA, Laurienti PJ, Kraft RA, Burdette JH. An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. Neuroimage 2003; 19: 1233-1239.
36. Engman J, Åhs F, Furmark T, Linnman C, Pissiota A, Appel L et al. Age, sex and NK1 receptors in the human brain - A positron emission tomography study with [11C] GR205171. Eur Neuropsychopharmacol 2012; 22: 562-568.
37. Nyman MJ, Eskola O, Kajander J, Vahlberg T, Sanabria S, Burns D et al. Gender and age affect NK1 receptors in the human brain - a positron emission tomography study with [18F]SPA-RQ. Int J Neuropsychopharmacol 2007; 10: 219-229.
38. Singewald N, Chicchi GG, Thurner CC, Tsao K-L, Spetea M, Schmidhammer H et al. Modulation of basal and stress-induced amygdaloid substance P release by the potent and selective NK1 receptor antagonist L-822429. J Neurochem 2008; 106: 2476-2488.
39. Sartory G, Cwik J, Knuppertz H, Schürholt B, Lebens M, Seitz RJ et al. In search of the trauma memory: a meta-analysis of functional neuroimaging studies of symptom provocation in posttraumatic stress disorder (PTSD). PLoS One 2013; 8: e58150.
40. Ipser JC, Singh L, Stein DJ. Meta-analysis of functional brain imaging in specific phobia. Psychiatry Clin Neurosci 2013; 67: 311-322.
41. Kwako LE, George DT, Schwandt ML, Spagnolo PA, Momenan R, Hommer DW et al. The neurokinin-1 receptor antagonist aprepitant in co-morbid alcohol dependence and posttraumatic stress disorder: a human experimental study. Psychopharmacology 2015; 232: 295-304.
42. Etkin A, Egner T, Kalisch R. Emotional processing in anterior cingulate and medial prefrontal cortex. Trends Cogn Sci 2011; 15: 85-93.
43. Motzkin JC, Philippi CL, Wolf RC, Baskaya MK, Koenigs M. Ventromedial prefrontal cortex is critical for the regulation of amygdala activity in humans. Biol Psychiatry 2015; 77: 276-284.
44. Etkin A, Wager TD. Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. Am J Psychiatry 2007; 164: 1476-1488.
45. McCabe C, Cowen PJ, Harmer CJ. NK1 receptor antagonism and the neural processing of emotional information in healthy volunteers. Int J Neuropsychopharmacol 2009; 12: 1261-1274.
46. Van der Wee NJ, van Veen JF, Stevens H, van Vliet IM, van Rijk PP, Westenberg HG. Increased serotonin and dopamine transporter binding in psychotropic medication-naive patients with generalized social anxiety disorder shown by 123I-beta-(4-iodophenyl)-tropane SPECT. J Nucl Med 2008; 49: 757-763.
47. Maron E, Tõru I, Hirvonen J, Tuominen L, Lumme V, Vasar V et al. Gender differences in brain serotonin transporter availability in panic disorder. J Psychopharmacol 2011; 25: 952-959.
48. Cannon DM, Klaver JM, Klug SA, Carlson PJ, Luckenbaugh DA, Ichise et al. Gender-specific abnormalities in the serotonin transporter system in panic disorder. Int J Neuropsychopharmacol 2013; 16: 733-743.
49. Zamuner S, Rabiner EA, Fernandes SA, Bani M, Gunn RN, Gomeni R et al. A pharmacokinetic PET study of NK1 receptor occupancy. Eur J Nucl Med Mol Imaging 2012; 39: 226-235.
50. Ratti E, Bellew K, Bettica P, Bryson H, Zamuner S, Archer G et al. Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorder. J Clin Psychopharmacol 2011; 31: 727-733.
51. Schank JR. The neurokinin-1 receptor in addictive processes. J Pharmacol Exp Ther 2014; 351: 2-8.
52. George DT, Gilman J, Hersh J, Thorsell A, Herion D, Geyer C et al. Neurokinin 1 receptor antagonism as a possible therapy for alcoholism. Science 2008; 319: 1536-1539.
53. Conway KP, Compton W, Stinson FS, Grant BF. Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the national epidemiologic survey on alcohol and related conditions. J Clin Psychiatry 2006; 67: 247-258.
54. Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, Compton W et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2004; 61: 807-816.
55. Mai JK, Assheuer J, Paxinos G. Atlas of the Human Brain. Academic Press: San Diego, CA, USA.
56. Zhao Z, Yang Y, Walker DL, Davis M. Effects of substance P in the amygdala, ventromedial hypothalamus, and periaqueductal gray on fear-potentiated startle. Neuropsychopharmacology 2008; 34: 331-340.
57. Dieleman GC, Huizink AC, Tulen JHM, Utens EMWJ, Creemers HE, van der Ende J et al. Alterations in HPA-axis and autonomic nervous system functioning in childhood anxiety disorders point to a chronic stress hypothesis. Psychoneuroendocrinology 2015; 51: 135-150.
58. Hwang BH, Katner J, Iyengar S. Corticotropin-releasing factor mRNA and substance P receptor binding in the paraventricular hypothalamic nucleus, central nucleus of the amygdala, and locus coeruleus of sprague-dawley rats following restraint-induced stress. J Mol Neurosci 2005; 25: 239-250.
59. Santarelli L, Gobbi G, Debs PC, Sibille EL, Blier P, Hen R et al. Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function. Proc Natl Acad Sci USA 2001; 98: 1912-1917.
60. Maron E, Nutt D, Shlik J. Neuroimaging of serotonin system in anxiety disorders. Curr Pharm Des 2012; 18: 5699-5708.
61. Gobbi G, Blier P. Effect of neurokinin-1 receptor antagonists on serotoninergic, noradrenergic and hippocampal neurons: comparison with antidepressant drugs. Peptides 2005; 26: 1383-1393.
62. Shirayama Y, Mitsushio H, Takashima M, Ichikawa H, Takahashi K. Reduction of substance P after chronic antidepressants treatment in the striatum, substantia nigra and amygdala of the rat. Brain Res 1996; 739: 70-78.
63. Juszczak M, Boczek-Leszczyk E. Oxytocin release from the rat neurohypophysis into the blood: effects of tachykinin NK-1 and NK-2 receptors agonists and antagonists. J Physiol Pharmacol 2008; 59: 553-562.
64. Phan KL, Coccaro EF, Angstadt M, Kreger KJ, Mayberg HS, Liberzon I et al. Corticolimbic brain reactivity to social signals of threat before and after sertraline treatment in generalized social phobia. Biol Psychiatry 2013; 73: 329-336.
65. Labuschagne I, Phan KL, Wood A, Angstadt M, Chua P, Heinrichs et al. Oxytocin attenuates amygdala reactivity to fear in generalized social anxiety disorder. Neuropsychopharmacology 2010; 35: 2403-2413.
66. Schank JR, Tapocik JD, Barbier E, Damadzic R, Eskay RL, Sun H et al. Tacr1 gene variation and neurokinin 1 receptor expression is associated with antagonist efficacy in genetically selected alcohol-preferring rats. Biol Psychiatry 2013; 73: 774-781.